NEWS
TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
TRACON Pharmaceuticals (NASDAQ: TCON) announced the publication of Phase 2 clinical data on its DNA damage repair inhibitor, TRC102, in recurrent glioblastoma patients.
Published in Clinical Cancer Research, the study evaluated TRC102 combined with Temodar in 19 patients who had progression following initial treatment.
Results showed extended survival in two patients, with progression-free survival of at least 17 months and overall survival over 32 months. Both patients had enriched DNA damage response pathways prior to treatment.
The study confirms the safety and feasibility of TRC102 with Temodar and suggests further trials in biomarker-enriched glioblastoma patients may be warranted.
Additionally, TRC102 is being studied in a Phase 2 trial for non-small cell lung cancer, with primary endpoint determination expected in 2025.
Published in Clinical Cancer Research, the study evaluated TRC102 combined with Temodar in 19 patients who had progression following initial treatment.
Results showed extended survival in two patients, with progression-free survival of at least 17 months and overall survival over 32 months. Both patients had enriched DNA damage response pathways prior to treatment.
The study confirms the safety and feasibility of TRC102 with Temodar and suggests further trials in biomarker-enriched glioblastoma patients may be warranted.
Additionally, TRC102 is being studied in a Phase 2 trial for non-small cell lung cancer, with primary endpoint determination expected in 2025.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1666Followers
93Following
13KVisitors
Follow